77
Participants
Start Date
May 31, 2004
Primary Completion Date
October 31, 2009
Study Completion Date
October 31, 2009
ipilimumab
IV over 90 mins on day 1, wks 1,9,17,25,33,41,53 Dose: 3 mg/kg (Part I), 10 mg/kg (Part II)
Tyrosinase/gp100/MART-1 Peptides
(All subjects in Part I and HLA-A\*0201 positive subjects only in Part II): SC, day 1 of wks 1,3,5,7,9,11,17, 21,25,33,41,53 Dose: 1 mg peptide emulsified in 1 mL Montanide ISA 51 VG.)
H. Lee Moffitt Cancer Center and Research Institute at University of South Florida, Tampa
Lead Sponsor
National Cancer Institute (NCI)
NIH
Bristol-Myers Squibb
INDUSTRY